News
The Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched new calls for the purposes of open access to its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs) and more in general to the public and private sector. More information on this initiative can be found here or in this JRC Brochure.
It concerns the following calls:
Nanobiotechnology Laboratory - Access Call (Deadline: 21 May 2024)
MONNET, Tandem accelerator based fast neutron source (EUFRAT) – Access Call (Deadline: 30 June 2024)
HADES, Underground laboratory for ultra-low level gamma-ray spectrometry (EUFRAT) – Access Call (Deadline: 30 June 2024)
GELINA, the JRC Neutron Time-of-Flight Facility (EUFRAT) – Access Call (Deadline 30 June 2024)
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
The network of National Contact Points (NCPs) for the European Research Council (ERC), mERCury, has recently published the first edition of the ERC Success Stories from Widening countries. The collection features seven ERC grantees from Malta, Croatia, Romania, Slovenia, Latvia, Greece and Türkiye who have received Starting, Consolidator,...
Read moreThe selected projects of the 2026 European Research Council (ERC) Synergy Grant call (call deadline 5 November 2025) were published by the ERC Executive Agency. Synergy grant projects consist of minimum two to maximum four researchers or Principal Investigators (PIs) and their teams that jointly address ambitious research problems that could...
Read moreThe new European Partnership for Resilient Cultural Heritage (RCH) that kicked off at the end of September has launched its first Joint Transnational Call (JTC): "Foundations for climate-resilient cultural heritage: Assessing and managing impact and risk, dealing with damage and loss". This first call within the RCH Partnership invites research...
Read moreNCP_WIDERA.NET, the WIDERA National Contact Points network, has so far put six projects, funded under the ERA part of the Horizon Europe WIDERA or Horizon 2020 Science with and for Society (Swafs) work programmes, in the spotlight in their ERA Success Stories series. The latest project example is COALESCE Advancing Leadership and Engagement in...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
